TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01887340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: - carboplatine: Dose (mg) = AUC x (GFR + 25)~* GFR : glomérulaire filtration (ml/min)~* AUC : area under curve (mg/ml x min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: - carboplatine: Dose (mg) = AUC x (GFR + 25)~* GFR : glomérulaire filtration (ml/min)~* AUC : area under curve (mg/ml x min)
Study: NCT04435795

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline intranasal and placebo inhaler
Description: Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Ciclesonide 600mcg BID inhaled with aero chamber

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide nasal
Description: intranasal ciclesonide 200 mcg DIE
Study: NCT01169805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron/single injection/4 mg/IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Ramosetron HCl/single injection/0.3mg/IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron HCl/single injection/0.075mg/IV
Study: NCT01887340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2 D1 to D5
Study: NCT01169805

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline inj
Description: normal saline injection 2ml
Study: NCT00913679

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical approach (ReCap Hip Resurfacing System)
Description: two different surgical approaches in hip resurfacing arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical approach (ReCap Hip Resurfacing System)
Description: two different surgical approaches in hip resurfacing arthroplasty
Study: NCT01887340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20 mg/m2 de D1 to D5
Study: NCT04330183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.3mg/kg of ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 3cc of normal saline
Study: NCT02413021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 20 mg/m\^2 , SC, two times a day for 10 days every 30 days for 1 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 20 mg/m\^2 , SC, two times a day for 10 days every 30 days for 1 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 20 mg/kg ,oral, per day
Study: NCT04386967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection
Description: Oncolytic Type 2 Herpes Simplex Virus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda
Description: Anti-PD-1 antibody
Study: NCT03564938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: The recommended dose of regorafenib is 160 mg (consisting of 4 tablets, each containing 40 mg of regorafenib) for 3 weeks of every 4 week cycle, (ie. 3 weeks on therapy, 1 week off therapy).
Study: NCT04041310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAd-209-FSP low dose
Description: GAd20-209-FSP IP, low dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-209-FSP low dose
Description: MVA-209-FSP IP, low dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAd-209-FSP high dose
Description: GAd20-209-FSP IP, high dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-209-FSP high dose
Description: MVA-209-FSP IP, high dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAd20-209-FSP, RP2D
Description: GAd20-209-FSP IP, RP2D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAd20-209-FSP, RP2D
Description: GAd20-209-FSP IP, RP2D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-209-FSP, RP2D
Description: MVA-209-FSP IP, RP2D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-209-FSP, RP2D
Description: MVA-209-FSP IP, RP2D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: anti-PD-1 checkpoint inhibitor (200 mg; Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: anti-PD-1 checkpoint inhibitor (200 mg; Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: anti-PD-1 checkpoint inhibitor (200 mg; Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: anti-PD-1 checkpoint inhibitor (200 mg; Q3W)
Study: NCT04672460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALZENNA capsule
Description: Current commercial talazoparib formulation 1 mg once daily given under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALZENNA capsule
Description: Current commercial talazoparib formulation 1 mg once daily given under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib soft gel capsule
Description: Proposed talazoparib soft gel capsule formulation 1 mg once daily under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib soft gel capsule
Description: Proposed talazoparib soft gel capsule formulation 1 mg once daily under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib soft gel capsule
Description: Proposed talazoparib soft gel capsule formulation 1 mg once daily under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib soft gel capsule
Description: Proposed talazoparib soft gel capsule formulation 1 mg once daily under fed condition
Study: NCT04339218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation will be performed by a specialized radiologist, percutaneously, ie through the skin. The operation is performed under general anesthesia, under the guidance of the scanner. The images from the scanner make it possible to precisely insert and place a needle at the level of the tumor to be treated. Intense cold will be produced by the needle and will destroy the cancer cells by freezing (temperatures of -40 °C). Freezing is localized to the tumor, the rest of the organ will not suffer from the cold.~The aftermath of the intervention causes only minimal pain and in most cases does not require pain treatment. As the operation is minimally traumatic, the risk of complications is low. Hospitalization is around twenty-four hours and usual or professional activities can be resumed very quickly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.
Study: NCT02665650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFM13

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT01991106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Twelve weeks of 2-3 supervised training sessions each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training
Description: Twelve weeks of 2-3 supervised training sessions each week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional advice
Description: healthy food choices, portion sizes and regular mealtimes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional advice
Description: healthy food choices, portion sizes and regular mealtimes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional advice
Description: healthy food choices, portion sizes and regular mealtimes
Study: NCT00742157

Intervention type: DRUG
Group type: OTHER
Intervention: Growth Hormone
Description: dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
Study: NCT00834236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal subject
Description: biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal subject
Description: biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gastric cancer
Description: biomarker in gastric juice, e.g., alpha 1-antitrypsin
Study: NCT04450212

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Phase I, Buccal Swab Collection for DNA Isolation
Description: Buccal swab will be taken from study participants for DNA isolation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phase II, Vitamin K (Vitacost) Supplementation
Description: 1-mg/day phylloquinone (Vitacost; Natures Life K-1 Phylloquinone) for 10 consecutive days. Each dose will be taken in the morning (\~ 8 am), with one half pint of 2% milk to facilitate absorption. Blood and urine samples collection before and during the vitamin K supplementation period.
Study: NCT03154567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yohimbine
Description: Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yohimbine
Description: Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine
Description: Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine
Description: Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine
Description: Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine
Description: Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
Study: NCT04010838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal cord stimulation
Description: The spinal cord stimulation(SCS) is a type of implantable neuromodulation device (spinal cord stimulator) that is used to send electrical signals to select areas of the spinal cord (C2-C4 in this study) for the treatment of disorders of consciousness.
Study: NCT01681849

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paroxetine
Description: Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.

Intervention type: OTHER
Group type: OTHER
Intervention: Positron Emission Tomography (PET) Imaging
Description: Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) Imaging
Description: Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Positron Emission Tomography (PET) Imaging
Description: Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
Study: NCT05080478

Intervention type: DRUG
Intervention: Clopidogrel, Ticagrelor
Description: P2Y12 inhibitors are prescribed following the PCI procedure in patients. Patients are enrolled on the study before administration of the first dose of the drug. Parameters are measured before and after drug initiation.

Intervention type: DRUG
Intervention: Clopidogrel, Ticagrelor
Description: P2Y12 inhibitors are prescribed following the PCI procedure in patients. Patients are enrolled on the study before administration of the first dose of the drug. Parameters are measured before and after drug initiation.
Study: NCT00667043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil and propofol
Description: Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl and midazolam
Description: Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
Study: NCT00834236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gastric cancer
Description: biomarker in gastric juice, e.g., alpha 1-antitrypsin
Study: NCT02661022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-401 7 µg/kg/day
Description: SL-401 7 µg/kg/day in combination with pom/dex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-401 9 µg/kg/day
Description: SL-401 9 µg/kg/day in combination with pom/dex
Study: NCT01164657

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: BirthRite
Description: Randomization takes place on admission to delivery unit, study group participants seated on the birthing seat when cervix is fully dilated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BirthRite
Description: Randomization takes place on admission to delivery unit, study group participants seated on the birthing seat when cervix is fully dilated.
Study: NCT03523650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Oral Tablet
Description: A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Propranolol Oral tablets, tid, for 36 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.
Study: NCT03044899

Intervention type: PROCEDURE
Intervention: All surgeries in adult patients
Description: All surgeries in adult patients
Study: NCT04339218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be prescribed and administered at the dose recommended by market authorization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be prescribed and administered at the dose recommended by market authorization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be prescribed and administered at the dose recommended by market authorization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be prescribed and administered at the dose recommended by market authorization.
Study: NCT00889382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously
Study: NCT02864550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: doxycycline 100mg orally daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group
Study: NCT00656539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaSite®
Description: Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Study: NCT03519490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Contact Lens
Description: Hybrid Single Vision or Multifocal Contact Lenses in Near Center and Distance Center Designs

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hybrid Contact Lens
Description: Hybrid Single Vision or Multifocal Contact Lenses in Near Center and Distance Center Designs
Study: NCT00840190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1446A-05
Description: P1446A-05 available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of P1446A-05. Four such cycles will be administered.
Study: NCT03901690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaglucin soluble gel 0.2%
Description: With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod 5% cream
Description: With the prior informed consent of the 51 study participants, 1 gram of 5% imiquimod will be self-applied once a day for 5 days. Both groups will receive an unlabeled tube so that neither study participant knows what topical treatments they are receiving.
Study: NCT02169336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Study: NCT00889382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously
Study: NCT02586285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Adenosyl Methionine
Description: 500mg-1000mg,iv,qd
Study: NCT00674973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants received erlotinib 150 mg tablet orally once daily.
Study: NCT02169336

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Study: NCT00970788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video intervention
Description: Video of goals of care
Study: NCT03711396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Care Planning Group Visits
Description: Pilot test the Advance Care Planning Group Visit intervention adaptations, called ENgaging in Advance Care planning Talks Group Visit intervention (ENACT Memory Group Visits), to see if it is feasible, acceptable and improves the number of people with amnestic mild cognitive impairment who complete an advance directive (a legal form that describes someone's wishes for future medical care if they are unable to make their own decisions). It will also see how ready individuals are to participate in advance care planning. The overall goal is to improve opportunities for older adults with amnestic mild cognitive impairment to receive medical care that is consistent with their values, goals, and preferences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Care Planning Group Visits
Description: Pilot test the Advance Care Planning Group Visit intervention adaptations, called ENgaging in Advance Care planning Talks Group Visit intervention (ENACT Memory Group Visits), to see if it is feasible, acceptable and improves the number of people with amnestic mild cognitive impairment who complete an advance directive (a legal form that describes someone's wishes for future medical care if they are unable to make their own decisions). It will also see how ready individuals are to participate in advance care planning. The overall goal is to improve opportunities for older adults with amnestic mild cognitive impairment to receive medical care that is consistent with their values, goals, and preferences.
Study: NCT04327336

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Non invasive ventilation titration
Description: Manual Group: during a complete polysomnography, adding transcutaneous capnography and the basic ventilators curves, the ventilators setting will be adjusted in order to correct respiratory events and patient-ventilator asyncrony. A 10 hours face-to-face investigator training meeting is programmed before opening the inclusion period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Non invasive ventilation titration
Description: Automatic Group: the A40 ventilator in the automatic AVAPS mode will be adjusted in order to achieve 8-10 ml/kg of ideal weight.
Study: NCT01148225

Intervention type: DRUG
Group type: OTHER
Intervention: adalimumab
Description: Adalimumab, pre-filled syringe, administered by SC injection
Study: NCT04698551

Intervention type: GENETIC
Intervention: Non invasive prenatal diagnosis
Description: Search for the familial mutation involved in DPN requests from phasing of parental haplotypes by 3rd generation long-fragment DNA sequencing techniques coupled with targeted sequencing of free circulating DNA from maternal plasma.
Study: NCT03062176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra (Kineret)
Study: NCT00889382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously